FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by…
31 Dec 2025
Emmaus, NIT sign Endari distribution agreement
Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a prescription-grade L-glutamine oral powder. The agreement grants NIT exclusive rights to distribute,…
30 Dec 2025
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including non-small cell lung cancer (NSCLC). Genmab remained brief on details,…
30 Dec 2025
Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash. This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform…
29 Dec 2025
Sanofi buys hep B vaccine maker for $2.2bn
Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's pipeline amid significant vaccine policy changes in the US. The…
29 Dec 2025
Revamping best-selling drugs to combat patent cliff has limits
As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making moves to try and reduce the impact. Patent expiry is…
29 Dec 2025
Innovent receives NMPA approval for Tabosun colon cancer treatment
Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application (NDA) for Tabosun (ipilimumab N01 injection), a CTLA-4 monoclonal antibody for colon cancer. The…